LGG®

Strain deposit number: ATCC53103

Lactobacillus rhamnosus GG (trademark LGG®) has been widely tested in more than 160 clinical studies from newborn preterm infants to elderly in doses up to at least 100 billion CFU/day with no reported side effects. Lactobacillus rhamnosus GG is considered safe based on its long history of use for human consumption and thorough safety studies.

The Benefits of Lactobacillus rhamnosus GG (trademark LGG®)

Human studies indicate that Lactobacillus rhamnosus GG may have a beneficial effect within gastrointestinal and immune function:

  • May reduce the risk of antibiotic associated side effects*
  • May improve stool consistency during antibiotic therapy*
  • May enhance the immune response after vaccination**
  • May potentially reduce respiratory infections***
  • May reduce the risk of nosocomial unsettled stomach****

Clinical documentation 

We have gathered abstracts of the studies, supporting the effects of Lactobacillus rhamnosus GG (trademark LGG®) in our Selected Summaries below. 

For more information please visit http://valio.com/solutions/valio-lgg/. LGG® is a registered trademark of Valio Ltd., Finland.

Contact

Contact Chr. Hansen's dedicated sales department - they will help you find the perfect product with strains from Chr. Hansen's Probio-Tec® range.

Downloads

LGG® Selected Summaries
LGG® Selected SummariesThis binder provides you with summaries of selected publications on LGG®

* Vanderhoof et al. 1999
** de Vrese et al. 2005
*** Hojsak et al. 2010a
**** Hojsak et al. 2010b